{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:48Z","timestamp":1791873468048,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81802284"],"award-info":[{"award-number":["81802284"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Taishan Scholar Foundation of Shandong Province","award":["tsqn202103179"],"award-info":[{"award-number":["tsqn202103179"]}]},{"name":"Science and Technology Development Plans of Shandong Province","award":["2014GSF118157"],"award-info":[{"award-number":["2014GSF118157"]}]},{"name":"Clinical Research Fund of Shandong Provincial Medical Association","award":["YXH2022ZX02176"],"award-info":[{"award-number":["YXH2022ZX02176"]}]},{"name":"Scientific Research Foundation of Shandong Province of Outstanding Young Scientists","award":["BS2013YY058"],"award-info":[{"award-number":["BS2013YY058"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00432-022-04196-7","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:03:38Z","timestamp":1657703018000},"page":"2029-2039","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations"],"prefix":"10.1007","volume":"149","author":[{"given":"Xiaoli","family":"Zhuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjiang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0893-7714","authenticated-orcid":false,"given":"Guobin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","volume":"18","author":"ME Arcila","year":"2012","unstructured":"Arcila ME, Chaft JE, Nafa K et al (2012) Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res 18:4910\u20134918. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0912","journal-title":"Clin Cancer Res"},{"key":"4196_CR2","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s12325-019-01001-9","volume":"36","author":"JB Auliac","year":"2019","unstructured":"Auliac JB, Do P, Bayle S et al (2019a) Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02\u201314. Adv Ther 36:2161\u20132166. https:\/\/doi.org\/10.1007\/s12325-019-01001-9","journal-title":"Adv Ther"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1007\/s12325-019-01001-9","volume":"36","author":"JB Auliac","year":"2019","unstructured":"Auliac JB, D\u00f4 P, Bayle S et al (2019b) Non-small cell lung cancer patients harboring HER2 mutations: clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02\u201314. Adv Ther 36:2161\u20132166. https:\/\/doi.org\/10.1007\/s12325-019-01001-9","journal-title":"Adv Ther"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1245\/s10434-015-5044-8","volume":"24","author":"S Bu","year":"2017","unstructured":"Bu S, Wang R, Pan Y et al (2017) Clinicopathologic characteristics of patients with HER2 insertions in non-small cell lung cancer. Ann Surg Oncol 24:291\u2013297. https:\/\/doi.org\/10.1245\/s10434-015-5044-8","journal-title":"Ann Surg Oncol"},{"key":"4196_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.lungcan.2015.01.013","volume":"88","author":"J De Greve","year":"2015","unstructured":"De Greve J, Moran T, Graas MP et al (2015) Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. Lung Cancer 88:63\u201369. https:\/\/doi.org\/10.1016\/j.lungcan.2015.01.013","journal-title":"Lung Cancer"},{"key":"4196_CR6","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2019.02.017","volume":"14","author":"R Dziadziuszko","year":"2019","unstructured":"Dziadziuszko R, Smit EF, Dafni U et al (2019) Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J Thorac Oncol 14:1086\u20131094. https:\/\/doi.org\/10.1016\/j.jtho.2019.02.017","journal-title":"J Thorac Oncol"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.lungcan.2020.07.017","volume":"147","author":"Y Fan","year":"2020","unstructured":"Fan Y, Chen J, Zhou C et al (2020) Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: a phase II trial. Lung Cancer 147:209\u2013213. https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.017","journal-title":"Lung Cancer"},{"key":"4196_CR8","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6:pl1. https:\/\/doi.org\/10.1126\/scisignal.2004088","journal-title":"Sci Signal"},{"key":"4196_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.celrep.2018.03.050","volume":"23","author":"Q Gao","year":"2018","unstructured":"Gao Q, Liang WW, Foltz SM et al (2018) Driver fusions and their implications in the development and treatment of human cancers. Cell Rep 23:227-238.e223. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.050","journal-title":"Cell Rep"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jtho.2020.04.028","volume":"15","author":"S Gao","year":"2020","unstructured":"Gao S, Li N, Wang S et al (2020) Lung cancer in People\u2019s Republic of China. J Thorac Oncol 15:1567\u20131576. https:\/\/doi.org\/10.1016\/j.jtho.2020.04.028","journal-title":"J Thorac Oncol"},{"key":"4196_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","volume":"15","author":"U Gatzemeier","year":"2004","unstructured":"Gatzemeier U, Groth G, Butts C et al (2004) Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 15:19\u201327. https:\/\/doi.org\/10.1093\/annonc\/mdh031","journal-title":"Ann Oncol"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","volume":"13","author":"K Hotta","year":"2018","unstructured":"Hotta K, Aoe K, Kozuki T et al (2018) A phase II study of Trastuzumab Emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol 13:273\u2013279. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.032","journal-title":"J Thorac Oncol"},{"key":"4196_CR13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nature25475","volume":"554","author":"DM Hyman","year":"2018","unstructured":"Hyman DM, Piha-Paul SA, Won H et al (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189\u2013194. https:\/\/doi.org\/10.1038\/nature25475","journal-title":"Nature"},{"key":"4196_CR14","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1200\/JCO.2004.04.105","volume":"22","author":"CJ Langer","year":"2004","unstructured":"Langer CJ, Stephenson P, Thor A et al (2004) Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598. J Clin Oncol 22:1180\u20131187. https:\/\/doi.org\/10.1200\/JCO.2004.04.105","journal-title":"J Clin Oncol"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.4143\/crt.2019.186","volume":"52","author":"K Lee","year":"2020","unstructured":"Lee K, Jung HA, Sun JM et al (2020) Clinical characteristics and outcomes of non-small cell lung cancer patients with HER2 alterations in Korea. Cancer Res Treat 52:292\u2013300. https:\/\/doi.org\/10.4143\/crt.2019.186","journal-title":"Cancer Res Treat"},{"key":"4196_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","volume":"11","author":"BT Li","year":"2016","unstructured":"Li BT, Ross DS, Aisner DL et al (2016a) HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers. J Thorac Oncol 11:414\u2013419. https:\/\/doi.org\/10.1016\/j.jtho.2015.10.025","journal-title":"J Thorac Oncol"},{"key":"4196_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_supll.e20666","author":"BT Li","year":"2016","unstructured":"Li BT, Zheng T, Ni A et al (2016b) Identifying HER2 mutation, amplification, and HER2 protein overexpression as therapeutic targets in lung cancers. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_supll.e20666","journal-title":"J Clin Oncol"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/jco.2018.77.9777","volume":"36","author":"BT Li","year":"2018","unstructured":"Li BT, Shen R, Buonocore D et al (2018) Ado-trastuzumab emtansine for patients with HER2-Mutant lung cancers: results from a phase II basket trial. J Clin Oncol 36:2532\u20132537. https:\/\/doi.org\/10.1200\/jco.2018.77.9777","journal-title":"J Clin Oncol"},{"key":"4196_CR19","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmab118","author":"M Li","year":"2021","unstructured":"Li M, Liu Y, Jiang X et al (2021) Inhibition of miR-144-3p exacerbates non-small cell lung cancer progression by targeting CEP55. Acta Biochim Biophys Sin. https:\/\/doi.org\/10.1093\/abbs\/gmab118","journal-title":"Acta Biochim Biophys Sin"},{"key":"4196_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.chest.2019.01.011","volume":"156","author":"K Ninomiya","year":"2019","unstructured":"Ninomiya K, Hata T, Yoshioka H et al (2019) A prospective cohort study to define the clinical features and outcome of lung cancers harboring HER2 aberration in Japan (HER2-CS STUDY). Chest 156:357\u2013366. https:\/\/doi.org\/10.1016\/j.chest.2019.01.011","journal-title":"Chest"},{"key":"4196_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ (2020) HER2-targeted therapies\u2014a role beyond breast cancer. Nat Rev Clin Oncol 17:33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4196_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","volume":"34","author":"KB Pahuja","year":"2018","unstructured":"Pahuja KB, Nguyen TT, Jaiswal BS et al (2018) Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell 34:792-806.e795. https:\/\/doi.org\/10.1016\/j.ccell.2018.09.010","journal-title":"Cancer Cell"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"84","DOI":"10.3978\/j.issn.2218-6751.2014.02.06","volume":"3","author":"S Peters","year":"2014","unstructured":"Peters S, Zimmermann S (2014) Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res 3:84\u201388. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2014.02.06","journal-title":"Transl Lung Cancer Res"},{"key":"4196_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/1759-7714.13317","volume":"11","author":"F Xu","year":"2020","unstructured":"Xu F, Yang G, Xu H et al (2020) Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China. Thorac Cancer 11:679\u2013685. https:\/\/doi.org\/10.1111\/1759-7714.13317","journal-title":"Thorac Cancer"},{"key":"4196_CR25","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1158\/1535-7163.Mct-14-0625","volume":"14","author":"S Yagishita","year":"2015","unstructured":"Yagishita S, Fujita Y, Kitazono S et al (2015) Chemotherapy-regulated microRNA-125-HER2 pathway as a novel therapeutic target for trastuzumab-mediated cellular cytotoxicity in small cell lung cancer. Mol Cancer Ther 14:1414\u20131423. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0625","journal-title":"Mol Cancer Ther"},{"key":"4196_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1200\/edbk_201331","volume":"38","author":"HA Yu","year":"2018","unstructured":"Yu HA, Planchard D, Lovly CM (2018) Sequencing therapy for genetically defined subgroups of non-small cell lung cancer. Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Ann Meet 38:726\u2013739. https:\/\/doi.org\/10.1200\/edbk_201331","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Ann Meet"},{"key":"4196_CR27","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1200\/jco.20.00297","volume":"38","author":"C Zhou","year":"2020","unstructured":"Zhou C, Li X, Wang Q et al (2020a) Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: a multicenter, open-label, single-arm, phase II study. J Clin Oncol 38:2753\u20132761. https:\/\/doi.org\/10.1200\/jco.20.00297","journal-title":"J Clin Oncol"},{"key":"4196_CR28","doi-asserted-by":"publisher","first-page":"175883592093609","DOI":"10.1177\/1758835920936090","volume":"12","author":"J Zhou","year":"2020","unstructured":"Zhou J, Ding N, Xu X et al (2020b) Clinical outcomes of patients with HER2-mutant advanced lung cancer: chemotherapies versus HER2-directed therapies. Ther Adv Med Oncol 12:1758835920936090. https:\/\/doi.org\/10.1177\/1758835920936090","journal-title":"Ther Adv Med Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04196-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04196-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T16:10:37Z","timestamp":1681315837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04196-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04196-7","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approved was granted by the ethics committee of the Shandong Provincial Affiliated First Medical University (Approval number NSFC: No. 2020-5001). Signed consent forms were obtained before participants were enrolled.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}